Screener
Hemab Therapeutics Holdings, Inc. COAG Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accrued expenses and other current liabilities | 2,002 | 316 |
| Operating lease liabilities | (316) | (281) |
| Other non-current liabilities | - | (17) |
| Net cash used in operating activities | (44,221) | (28,366) |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (148,208) | (19,948) |
| Maturities of available-for-sale debt securities | 25,059 | 35,472 |
| Purchases of property and equipment | (135) | (16) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s operating cash flow?
- Hemab Therapeutics Holdings, Inc. (COAG) reported operating cash flow of -$22.64M in Q2 2026.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude